Orexin Inhibitor Side Effects and Safety Profile

Common Adverse Effects

Somnolence (daytime drowsiness) is the most common side effect of orexin inhibitors like suvorexant, occurring in approximately 7% of patients compared to 3% with placebo 1, 2

Amnesia, anxiety, and hallucinations are listed as potential neuropsychiatric symptoms 1, 2

Somnolence increases in a dose-dependent manner, with higher frequencies at doses exceeding FDA-recommended levels 2
Higher doses (30-40 mg) showed better efficacy but were rejected by the FDA specifically due to dose-dependent increases in daytime somnolence (up to 8.4% versus 3.1% with placebo at 15/20 mg doses) 2
Lower doses (5-10 mg) offer improved safety profiles while maintaining efficacy for sleep maintenance 1, 4

Profuse sweating (hyperhidrosis) has been reported, though not well-documented in clinical trials 4
The mechanism may involve orexin system effects on autonomic nervous system regulation and thermoregulatory centers 4
Sweating may be part of a mild serotonergic syndrome, particularly if patients are on concomitant SSRIs or other serotonergic agents 4

Suvorexant does not cause the severe adverse effects associated with zolpidem, such as amnesia, vertigo, confusion, and diplopia 3

Monitor for drug interactions with SSRIs and other serotonergic agents, which may have additive effects 4

No dose adjustment is needed for advanced age according to the American Geriatrics Society 1

The absolute effect versus placebo is small, with subjective total sleep time improvements of only 5.5-10.6 minutes at approved doses 2
Despite modest efficacy, the frequency and severity of adverse effects are generally lower than with traditional hypnotics 3
Cognitive behavioral therapy for insomnia (CBT-I) should be first-line treatment, with suvorexant reserved as second-line when CBT-I is unsuccessful 1, 2
Residual morning sedation can occur, though absolute rates are generally low 3